| Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped E Louis, JY Mary, G Vernier–Massouille, JC Grimaud, Y Bouhnik, ... Gastroenterology 142 (1), 63-70. e5, 2012 | 755 | 2012 |
| Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease K Karmiris, G Paintaud, M Noman, C Magdelaine–Beuzelin, M Ferrante, ... Gastroenterology 137 (5), 1628-1640, 2009 | 603 | 2009 |
| Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial G Van Assche, C Magdelaine–Beuzelin, G d'Haens, F Baert, M Noman, ... Gastroenterology 134 (7), 1861-1868, 2008 | 593 | 2008 |
| Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship S Dall’Ozzo, S Tartas, G Paintaud, G Cartron, P Colombat, P Bardos, ... Cancer research 64 (13), 4664-4669, 2004 | 559 | 2004 |
| Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output S Dupuis-Girod, I Ginon, JC Saurin, D Marion, E Guillot, E Decullier, ... Jama 307 (9), 948-955, 2012 | 433 | 2012 |
| Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease E Louis, Z El Ghoul, S Vermeire, S Dall'Ozzo, P Rutgeerts, G Paintaud, ... Alimentary pharmacology & therapeutics 19 (5), 511-519, 2004 | 290 | 2004 |
| Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease S Rajca, V Grondin, E Louis, G Vernier-Massouille, JC Grimaud, ... Inflammatory bowel diseases 20 (6), 978-986, 2014 | 272 | 2014 |
| Infliximab pharmacokinetics in inflammatory bowel disease patients D Ternant, A Aubourg, C Magdelaine-Beuzelin, D Degenne, H Watier, ... Therapeutic drug monitoring 30 (4), 523-529, 2008 | 236 | 2008 |
| Mechanism-based pharmacokinetic–pharmacodynamic modeling—a new classification of biomarkers M Danhof, G Alvan, SG Dahl, J Kuhlmann, G Paintaud Pharmaceutical research 22, 1432-1437, 2005 | 219 | 2005 |
| Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases E Ducourau, D Mulleman, G Paintaud, DC Miow Lin, F Lauféron, ... Arthritis research & therapy 13, 1-7, 2011 | 205 | 2011 |
| Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant … B Coudert, JY Pierga, MA Mouret-Reynier, K Kerrou, JM Ferrero, T Petit, ... The Lancet Oncology 15 (13), 1493-1502, 2014 | 155 | 2014 |
| An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab D Ternant, D Mulleman, D Degenne, S Willot, JM Guillaumin, H Watier, ... Therapeutic drug monitoring 28 (2), 169-174, 2006 | 153 | 2006 |
| Pharmacokinetics of rituximab and its clinical use: thought for the best use? G Cartron, H Blasco, G Paintaud, H Watier, C Le Guellec Critical reviews in oncology/hematology 62 (1), 43-52, 2007 | 141 | 2007 |
| Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins D Ternant, G Paintaud Expert opinion on biological therapy 5 (sup1), S37-S47, 2005 | 140 | 2005 |
| Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients C Le Guellec, H Bourgoin, M Büchler, Y Le Meur, Y Lebranchu, P Marquet, ... Clinical pharmacokinetics 43, 253-266, 2004 | 139 | 2004 |
| Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20 D Daydé, D Ternant, M Ohresser, S Lerondel, S Pesnel, H Watier, ... Blood, The Journal of the American Society of Hematology 113 (16), 3765-3772, 2009 | 137 | 2009 |
| Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients N Azzopardi, T Lecomte, D Ternant, M Boisdron-Celle, F Piller, A Morel, ... Clinical Cancer Research 17 (19), 6329-6337, 2011 | 128 | 2011 |
| Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator A Rousseau, F Leger, Y Le Meur, F Saint-Marcoux, G Paintaud, M Buchler, ... Therapeutic drug monitoring 26 (1), 23-30, 2004 | 120 | 2004 |
| Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis D Ternant, T Bejan-Angoulvant, C Passot, D Mulleman, G Paintaud Clinical pharmacokinetics 54 (11), 1107-1123, 2015 | 114 | 2015 |
| Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system L Guilleminault, N Azzopardi, C Arnoult, J Sobilo, V Hervé, J Montharu, ... Journal of Controlled Release 196, 344-354, 2014 | 114 | 2014 |